이 페이지의 번역은 실험적이며 개발 중입니다. 여러분의 환영합니다!

Changmao Biochemical Engineering 미래 성장

Future 기준 확인 0/6

현재 Changmao Biochemical Engineering 의 성장과 수익을 예측할 만큼 분석가의 범위가 충분하지 않습니다.

주요 정보

n/a

수익 성장률

n/a

EPS 성장률

Chemicals 수익 성장	46.6%
매출 성장률	n/a
향후 자기자본 수익률	n/a
애널리스트 커버리지	None
마지막 업데이트	n/a

최근 미래 성장 업데이트

Recent updates

Investors Will Want Changmao Biochemical Engineering's (HKG:954) Growth In ROCE To Persist

Aug 02

Returns On Capital At Changmao Biochemical Engineering (HKG:954) Have Stalled

Nov 18

We Believe Changmao Biochemical Engineering's (HKG:954) Earnings Are A Poor Guide For Its Profitability

Apr 28

Changmao Biochemical Engineering (HKG:954) Will Be Looking To Turn Around Its Returns

Aug 03

Changmao Biochemical Engineering (HKG:954) May Have Issues Allocating Its Capital

May 04

Tread With Caution Around Changmao Biochemical Engineering Company Limited's (HKG:954) 8.8% Dividend Yield

Feb 23

Will Changmao Biochemical Engineering (HKG:954) Multiply In Value Going Forward?

Jan 26

A Quick Analysis On Changmao Biochemical Engineering's (HKG:954) CEO Salary

Dec 02

이 섹션에서는 일반적으로 투자자가 회사의 수익 창출 능력을 이해하는 데 도움이 되도록 전문 애널리스트의 컨센서스 추정치를 기반으로 수익 및 수익 성장 전망치를 제시합니다. 하지만 Changmao Biochemical Engineering 은 충분한 과거 데이터를 제공하지 않았고 애널리스트 예측도 없기 때문에 과거 데이터를 추정하거나 애널리스트 예측을 사용하여 미래 수익을 안정적으로 계산할 수 없습니다.

SimplyWall St에서 다루는 기업의 97%가 과거 재무 데이터를 가지고 있기 때문에 이는 매우 드문 상황입니다.

수익 및 매출 성장 예측

SEHK:954 - 애널리스트의 미래 추정치 및 과거 재무 데이터 (CNY Millions )
날짜	수익	수익	잉여 현금 흐름	작전 현금	평균 애널리스트 수
12/31/2023	637	-86	-142	-2	N/A
9/30/2023	640	-21	-170	-12	N/A
6/30/2023	644	45	-199	-22	N/A
3/31/2023	687	63	-202	-1	N/A
12/31/2022	730	81	-204	20	N/A
9/30/2022	707	90	-211	25	N/A
6/30/2022	684	99	-217	31	N/A
3/31/2022	616	79	-201	12	N/A
12/31/2021	548	58	-184	-7	N/A
9/30/2021	509	30	N/A	N/A	N/A
6/30/2021	471	2	-98	14	N/A
3/31/2021	457	9	-59	36	N/A
12/31/2020	444	17	-21	59	N/A
9/30/2020	430	24	N/A	N/A	N/A
6/30/2020	417	31	39	84	N/A
3/31/2020	456	45	58	101	N/A
12/31/2019	495	58	77	118	N/A
9/30/2019	557	69	64	97	N/A
6/30/2019	620	79	51	76	N/A
3/31/2019	629	65	31	60	N/A
12/31/2018	639	51	12	44	N/A
9/30/2018	633	34	24	60	N/A
6/30/2018	626	17	36	75	N/A
3/31/2018	629	10	26	70	N/A
12/31/2017	631	3	16	66	N/A
9/30/2017	625	8	N/A	61	N/A
6/30/2017	619	13	N/A	57	N/A
3/31/2017	607	23	N/A	53	N/A
12/31/2016	594	33	N/A	49	N/A
9/30/2016	569	42	N/A	47	N/A
6/30/2016	544	51	N/A	46	N/A
3/31/2016	530	48	N/A	59	N/A
12/31/2015	515	45	N/A	72	N/A
9/30/2015	519	40	N/A	82	N/A
6/30/2015	523	35	N/A	91	N/A
3/31/2015	543	36	N/A	94	N/A
12/31/2014	562	37	N/A	96	N/A
9/30/2014	606	48	N/A	91	N/A
6/30/2014	650	58	N/A	85	N/A
3/31/2014	677	66	N/A	N/A	N/A
12/31/2013	703	70	N/A	69	N/A
9/30/2013	699	60	N/A	N/A	N/A

애널리스트 미래 성장 예측

수입 대 저축률: 954 의 예상 수익 증가율이 절약률( 2.2% )보다 높은지 판단하기에는 데이터가 부족합니다.

수익 vs 시장: 954 의 수익이 Hong Kong 시장보다 빠르게 성장할 것으로 예상되는지 판단하기에는 데이터가 부족합니다.

고성장 수익: 954 의 수익이 향후 3년 동안 상당히 증가할 것으로 예상되는지 판단하기에는 데이터가 부족합니다.

수익 대 시장: 954 의 수익이 Hong Kong 시장보다 빠르게 성장할 것으로 예상되는지 판단하기에는 데이터가 부족합니다.

고성장 수익: 954 의 수익이 연간 20% 보다 빠르게 증가할 것으로 예상되는지 판단하기에는 데이터가 부족합니다.

주당 순이익 성장 예측

미래 자기자본 수익률

미래 ROE: 954 의 자기자본수익률이 3년 내에 높을 것으로 예상되는지 판단하기에는 데이터가 부족합니다.

Changmao Biochemical Engineering 미래 성장

Future 기준 확인 0/6

주요 정보

최근 미래 성장 업데이트

Changmao Biochemical Engineering Company Limited Provides Consolidated Earnings Guidance for the Six Months Ended June 30, 2022

Changmao Biochemical Engineering Company Limited Provides Earnings Guidance for the Year Ended 31 December 2020

Recent updates

Chairman & Compliance Officer recently bought HK$132k worth of stock

Chairman & Compliance Officer recently bought HK$836k worth of stock

Chairman & Compliance Officer recently bought HK$164k worth of stock

Changmao Biochemical Engineering Company Limited, Annual General Meeting, May 28, 2024

Full year 2023 earnings released: CN¥0.16 loss per share (vs CN¥0.15 profit in FY 2022)

New minor risk - Financial data availability

Changmao Biochemical Engineering Company Limited to Report Fiscal Year 2023 Results on Mar 26, 2024

Chairman & Compliance Officer recently bought HK$59k worth of stock

Chairman & Compliance Officer recently bought HK$231k worth of stock

Chairman & Compliance Officer recently bought HK$54k worth of stock

Chairman & Compliance Officer recently bought HK$327k worth of stock

Chairman & Compliance Officer recently bought HK$277k worth of stock

New major risk - Financial position

First half 2023 earnings released: EPS: CN¥0.008 (vs CN¥0.077 in 1H 2022)

Changmao Biochemical Engineering Company Limited to Report First Half, 2023 Results on Aug 18, 2023

Investors Will Want Changmao Biochemical Engineering's (HKG:954) Growth In ROCE To Persist

Now 21% undervalued after recent price drop

Now 22% undervalued after recent price drop

Changmao Biochemical Engineering Company Limited approves Final Dividend for the Year Ended 31 December 2022, Payable on 18 July 2023

Upcoming dividend of CN¥0.077 per share at 8.4% yield

Full year 2022 earnings released: EPS: CN¥0.15 (vs CN¥0.11 in FY 2021)

Returns On Capital At Changmao Biochemical Engineering (HKG:954) Have Stalled

Less than half of directors are independent

First half 2022 earnings released: EPS: CN¥0.077 (vs CN¥0 in 1H 2021)

Changmao Biochemical Engineering Company Limited Announces Appointment of Ms. Cheng Mun Wah as Independent Non-Executive Director and Chairman of Audit Committee, and Member of Remuneration Committee and Nomination Committee

First half 2022 earnings released: EPS: CN¥0 (vs CN¥0 in 1H 2021)

Changmao Biochemical Engineering Company Limited to Report First Half, 2022 Results on Aug 18, 2022

Changmao Biochemical Engineering Company Limited Provides Consolidated Earnings Guidance for the Six Months Ended June 30, 2022

Changmao Biochemical Engineering Company Limited Appoints Cheng Mun Wah as Independent Non-Executive Director and Chairman of Audit Committee and Member of Remuneration Committee and Nomination Committee

Changmao Biochemical Engineering Company Limited Approves Board Resignations, Effective 18 June 2022

We Believe Changmao Biochemical Engineering's (HKG:954) Earnings Are A Poor Guide For Its Profitability

Less than half of directors are independent

Changmao Biochemical Engineering Company Limited Omits Final Dividend for the Year Ended 31 December 2021

Full year 2021 earnings released

Changmao Biochemical Engineering (HKG:954) Will Be Looking To Turn Around Its Returns

Upcoming dividend of CN¥0.02 per share

Changmao Biochemical Engineering (HKG:954) May Have Issues Allocating Its Capital

Full year 2020 earnings released: EPS CN¥0.032 (vs CN¥0.11 in FY 2019)

Full year 2020 earnings released

Changmao Biochemical Engineering Company Limited Provides Earnings Guidance for the Year Ended 31 December 2020

Changmao Biochemical Engineering Company Limited to Report Fiscal Year 2020 Results on Mar 30, 2021

Tread With Caution Around Changmao Biochemical Engineering Company Limited's (HKG:954) 8.8% Dividend Yield

Will Changmao Biochemical Engineering (HKG:954) Multiply In Value Going Forward?

New 90-day high: HK$0.65

A Quick Analysis On Changmao Biochemical Engineering's (HKG:954) CEO Salary

New 90-day low: HK$0.56

First half earnings released

New 90-day low - HK$0.59

First half earnings released

Changmao Biochemical Engineering Company Limited to Report First Half, 2020 Results on Aug 28, 2020

New 90-day low - HK$0.60

수익 및 매출 성장 예측

애널리스트 미래 성장 예측

주당 순이익 성장 예측

미래 자기자본 수익률

성장 기업 발견